Yunjuan  Gu

Dr. Yunjuan Gu


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2013 in Journal of Proteome Research
Verified
Journal Article
Closed access
YGYunjuan Gu
Yunjuan Gu
AZAihua Zhao
Aihua Zhao
FHFengjie Huang
Fengjie Huang
YZYinan Zhang
Yinan Zhang
JLJiajian Liu
Jiajian Liu
WJWeiping Jia
Weiping Jia

2 November 2015 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
ZDZixuan Deng
Zixuan Deng
YGYunjuan Gu
Yunjuan Gu
XHXuhong Hou
Xuhong Hou
LZLei Zhang
Lei Zhang
YBYuqian Bao
Yuqian Bao
WJWeiping Jia
Weiping Jia

14 March 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
YGYunjuan Gu
Yunjuan Gu
HYHaoyong Yu
Haoyong Yu
YLYuehua Li
Yuehua Li
XMXiaojing Ma
Xiaojing Ma
JLJunxi Lu
Junxi Lu
WJWeiping Jia
Weiping Jia
Aim. To investigate the effects of weight loss during an 8-week very low carbohydrate diet (VLCD) on improvement of metabolic parameters, adipose distribution and body composition, and insulin resistance and sensitivity in Chinese obese subjects.Methods. Fifty-three healthy obese volunteers were given an 8-week VLCD. The outcomes were changes in anthropometry, body composition, metabolic profile, abdominal fat distribution, liver fat percent (LFP), and insulin resistance and sensitivity.Results. A total of 46 (86.8%) obese subjects completed the study. The VLCD caused a weight loss of−8.7±0.6 kg (mean ± standard error (SE),P<0.0001) combined with a significant improvement of metabolic profile. In both male and female, nonesterified fatty acid (NEFA) significantly decreased (−166.2±47.6 μmol/L,P=0.001) andβ-hydroxybutyric acid (BHA) increased (0.15±0.06 mmol/L,P=0.004) after eight weeks of VLCD intervention. The significant reductions in subcutaneous fat area (SFA), visceral fat area (VFA), and LFP were−66.5±7.9 cm2,−35.3±3.9 cm2, and−16.4±2.4%, respectively (allPvaluesP<0.0001). HOMA IR and HOMAβsignificantly decreased while whole body insulin sensitivity index (WBISI) increased (allPvaluesP<0.001).Conclusion. Eight weeks of VLCD was an effective intervention in obese subjects. These beneficial effects may be associated with enhanced hepatic and whole-body lipolysis and oxidation.

7 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YGYunjuan Gu
Yunjuan Gu
CWChunfang Wang
Chunfang Wang
YZYing Zheng
Ying Zheng
XHXuhong Hou
Xuhong Hou
YMYifei Mo
Yifei Mo
WJWeiping Jia
Weiping Jia
The aim was to investigate the association between human insulin and cancer incidence and mortality in Chinese patients with type 2 diabetes. We recruited 8,774 insulin-naïve diabetes patients from the Shanghai Diabetes Registry (SDR). The follow-up rate was 85.4%. All subjects were divided into the insulin use cohort (n = 3,639) and the non-insulin use cohort (n = 5,135). The primary outcome was the first diagnosis of any cancer. The secondary outcome was all-cause mortality. Cox proportional hazards model was used to estimate the relative risk (RR) of cancer and mortality. We observed 98 cancer events in the insulin use cohort and 170 in the non-insulin use cohort. Cancer incidence rates were 78.6 and 74.3 per 10,000 patients per year in the insulin users and the non-insulin users, respectively. No significant difference in cancer risk was observed between the two cohorts (adjusted RR = 1.20, 95% CI 0.89–1.62, P = 0.228). Regarding site-specific cancers, only the risk of liver cancer was significantly higher in the insulin users compared to that in the non-insulin users (adjusted RR = 2.84, 95% CI 1.12–7.17, P = 0.028). The risks of overall mortality (adjusted RR = 1.89, 95% CI 1.47–2.43, P<0.0001) and death from cancer (adjusted RR = 2.16, 95% CI 1.39–3.35, P = 0.001) were all significantly higher in the insulin users than in the non-insulin users. There was no excess risk of overall cancer in patients with type 2 diabetes who were treated with human insulin. However, a significantly higher risk of liver cancer was found in these patients. Moreover, insulin users showed higher risks of overall and cancer mortality. Considering that individuals treated with insulin were more likely to be advanced diabetic patients, caution should be used in interpreting these results.

YGYunjuan Gu
Yunjuan Gu
XHXuhong Hou
Xuhong Hou
YZYing Zheng
Ying Zheng
CWChunfang Wang
Chunfang Wang
LZLei Zhang
Lei Zhang
SCShiwei Cui
Shiwei Cui
Background: Evidence from epidemiologic investigation indicates that people with type 2 diabetes (T2DM) are at a significantly higher risk of many types of cancer and mortality. The aim of this study was to investigate the incidence and mortality risks of cancer in patients with T2DM compared with the general population in Shanghai, China. Methods: Based on the Shanghai Diabetes Registry (SDR) database linking to the Shanghai Cancer Registry and Surveillance System (SCRSS), a total of 12,276 T2DM patients without cancer were defined and followed up from 1 December 2001 to 31 July 2011. Standardized incidence ratio (SIR) and standardized mortality ratio (SMR) with 95% confidence interval (CI) were calculated using the whole gender and age-matched general population of Shanghai as a reference during the same period. Results: The overall cancer risk was found higher in both males and females T2DM patients, with the SIR of 3.14 (95% CI 2.73–3.56) and 4.29 (95% CI 3.64–4.94), respectively. The overall mortality risk of cancer also significantly increased with the SMR of 2.27 (95% CI 1.86–2.68) and 1.86 (95% CI 1.46–2.26), respectively. Pancreatic cancer was with the highest SIR and SMR in both genders. Conclusions: Compared with the general population, patients with T2DM were associated with higher incidence and mortality risks of cancer, especially pancreatic cancer.

1 March 2012 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
YGYunjuan Gu
Yunjuan Gu
XHXuhong Hou
Xuhong Hou
LZLei Zhang
Lei Zhang
JPJiemin Pan
Jiemin Pan
QCQingxia Cai
Qingxia Cai
WJWeiping Jia
Weiping Jia
Background: The present study evaluated the efficacy of biphasic human insulin 30 (BHI 30) in type 2 diabetes patients who had failed in therapy with two or more oral antidiabetes drugs (OADs). Methods: This open-label, nonrandomized, 4-month, multicenter, clinical observational study was conducted in Shanghai, China. A total of 660 insulin-naive type 2 diabetes patients with poor glycemic control (glycosylated hemoglobin [HbA1c] ≥7.5%), despite treatment with two or more OADs for more than 6 months, were recruited and received BHI 30 monotherapy or BHI 30 plus OAD(s) (metformin only, α-glucosidase inhibitor only, or both). Results: Among the 660 subjects, 644 completed the 4-month study. At the end of the study, the median level of HbA1c decreased by 2.0% (from 9.1% to 7.0%) in the BHI 30 monotherapy group and also 2.0% (from 9.5% to 7.3%) in the BHI 30 plus OAD group. More patients achieved the HbA1c <7.0% target in the BHI 30 monotherapy group than in the BHI 30 plus OAD(s) group (47.9% vs. 35.3%, P=0.002). Compared with the expenses of the prior treatment strategy, the median daily cost decreased by 39.8% (4.5 yuan, Chinese RMB) at the end point in the BHI 30 monotherapy group but increased by 20.0% (2.2 yuan) in the BHI 30 plus OAD(s) group (P<0.0001). Moreover, patients in the BHI 30 plus OAD(s) group had fewer minor hypoglycemic episodes than in the BHI 30 monotherapy group (mean of 1.06 vs. 2.77 per patient per year, P<0.0001). Conclusions: Short-term BHI 30 therapy can improve glycemic control in insulin-naive type 2 diabetes patients after failure of two or more OADs. With higher baseline glucose level, the BHI 30 plus OAD(s) group had lower pharmacoeconomic efficacy than the BHI 30 monotherapy group despite having fewer hypoglycemia events.